Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial.

Name: Kaimen Rigor review — Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial.
Item: Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial.
Rating: 100
Author: Alpha1

Stanley C, Mallik R, Hamid N, Jassil FC, Reuven V, Ruwona T, Dicken SJ, Qamar S, Norton B, Kingett H, Pucci A, Magee C, Boniface D, Batterham RL, Devalia K, Mok J, Elkalaawy M, Loy J, Jenkinson A, Markakis H, Adamo M, Brown A, Makaronidis J

Paper source

Read full text (PMC)

Embed this Rigor badge

Kaimen Rigor review — 3.5★ (Adequate), 0 critical, 2 high issues for “Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial.”

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 15, 2026

Read alongside

Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial.

Read full text (PMC)

DOI

10.1038/s41591-026-04416-4

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/0520c931-38e8-486d-b7e7-b11ea8212edb" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/0520c931-38e8-486d-b7e7-b11ea8212edb/badge" alt="Kaimen Rigor review — 3.5★ (Adequate), 0 critical, 2 high issues for “Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

e17cf994ad222cb514355f4fdb4564d117fdab12392d817cef881635ae42198f

Verify via API

Issued Aug 15, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Alpha¹ by Kaimen

Fetching the latest research

Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial.

Paper source

Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial.

Read full text (PMC)

Embed this Rigor badge

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 15, 2026

Kaimen Rigor review

Kaimen Rigor reviewed

3.5 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsOverstated claim−0.5★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Biggest issues

01Conclusion reaches beyond the evidence
mediumOverreachreviewer-assessedFull detail
Semaglutide 2.4 mg may rival weight loss results from revisional metabolic surgery.
“Additionally, we provide important clinical evidence that 68 weeks of semaglutide 2.4 mg weekly may rival weight loss results from revisional metabolic surgery when undertaken for weight optimization after a suboptimal outcome to a primary surgical procedure”
Discussion ¶5Find in source

Findings by category

101ArithmeticNumerical inconsistencies 202OverreachOverstated conclusions 03AuthenticityNone found 04DisclosureNone found 05AvailabilityNone found 06Copyedit5 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and transparently reported randomized controlled trial with rigorous design, clear ethical approvals, and comprehensive reporting. Minor internal inconsistencies in adverse event counts and a slightly overstated claim about rivaling revisional surgery are the main weaknesses.

Both reviewers classified the study as interventional, and this was adopted. The evaluation covered the full text, with verification of statistics (7 tests recomputed consistently), citations (no retracted or not-found references), and reproducibility (GitHub link live). The GRIM/GRIMMER checks were not applicable due to continuous outcomes.

Numerical inconsistencies

1 finding · worst low

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Recomputed 7 tests: 7 consistent, 0 inconsistent; 2 recomputed directly from the reported test statistics, 5 via agent-written checks.

Overstated conclusions

2 findings · worst medium

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Conclusions overstated beyond the evidenceAssessed
Conclusions only partially backed by the presented evidenceAssessed

6 major claims checked against the paper's own evidence: 1 not fully backed by the presented evidence (unsupported or overstated), 1 only partially supported (evidence backs part of the claim; gaps or caveats remain).

Efficacy claim is anchored to an adequate endpoint and a meaningful effect.

Data authenticity concerns

None found

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Checked — nothing surfaced.

Reporting gaps

None found

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Checked — nothing surfaced.

Eight Dimensions8 pass

The introduction cites prior studies (GRAVITAS, BARI-OPTIMISE, STEP program) and explains the rationale for testing semaglutide in this population. It acknowledges gaps, such as the lack of a randomized trial for semaglutide in post-bariatric patients with suboptimal response. Limitations of prior work are addressed by designing a trial with a longer duration and a more potent GLP-1RA.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise with extensive prior work cited, a logical rationale, and addresses limitations of prior research.

Evidence

“The GRAVITAS trial demonstrated that, in individuals with persistent or recurrent T2D after MBS, liraglutide 1.8 mg daily as an adjunct to lifestyle intervention, improved glycemic control with a mean weight difference of −4.2 kg (95% confidence interval (CI) −6.8 to −1.4) after 26 weeks.”

Introduction ¶3Find in source

“Considering the promising results from the BARI-OPTIMISE trial and the STEP program, we hypothesized that once-weekly semaglutide 2.4 mg will lead to greater weight loss and health improvement compared to placebo in patients with a suboptimal clinical response after MBS.”

IntroductionFind in source

paraphrase[Discussion, paragraph 2]

“Paraphrase: The authors note that BARI-OPTIMISE selectively recruited patients with blunted GLP-1 response, and BARI-STEP does not require this, addressing a potential limitation.”

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise with extensive prior work cited, a logical rationale, and addresses limitations of prior research.

Evidence

“To our knowledge, there is no randomized clinical trial evaluating the safety and efficacy of semaglutide 2.4 mg for a suboptimal clinical response after MBS.”

Introduction ¶4Find in source

“we hypothesized that once-weekly semaglutide 2.4 mg will lead to greater weight loss and health improvement compared to placebo in patients with a suboptimal clinical response after MBS.”

Introduction ¶4Find in source

“BARI-OPTIMISE demonstrated comparatively higher %WL to the SCALE trial; however, given the trial design, a relationship between the lower native GLP-1 levels in the trial population and the higher %WL could not be inferred.”

Discussion ¶3Find in source

Randomization was computer-generated and stratified by surgery type, sex, and diabetes status. Blinding of participants and clinical personnel is described. A sample size calculation is provided with assumptions. Inclusion/exclusion criteria are detailed. The analysis population (ITT) is defined, and missing data handled via inverse probability weighting. The trial is registered and follows CONSORT.

Sub-criteria

controlsN/A

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous with adequate randomization, blinding, power analysis, and pre-specified inclusion/exclusion criteria.

Evidence

“Randomization was carried out by a computer-generated randomization sequence (sealed envelope) stratified according to surgical procedure type (GB versus SG), sex and T2D status.”

MethodsFind in source

“Written informed consent was obtained and all participants and clinical study personnel were blinded.”

MethodsFind in source

“Assuming an s.d. for %WL of 4.0, a dropout rate of 10% and 1% critical significance level, 62 patients (31 per group) would provide at least 95% power to detect an estimated difference of 10%WL with a 95% CI no wider than 8.0 to 12.0.”

MethodsFind in source

PASSReviewer 2· 95% conf

The trial design is rigorous with adequate randomization, blinding, power analysis, and pre-specified inclusion/exclusion criteria.

Evidence

“Randomization was carried out by a computer-generated randomization sequence (sealed envelope) stratified according to surgical procedure type (GB versus SG), sex and T2D status.”

MethodsFind in source

“Written informed consent was obtained and all participants and clinical study personnel were blinded.”

MethodsFind in source

Sex is reported for all participants, and both sexes are included, so no justification for single-sex is needed. Age, weight, BMI, and health status (diabetes) are reported. Demographics include ethnicity. Species/strain and housing are not applicable as this is a human trial.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Biological variables including sex, age, weight, and demographics are well reported.

Evidence

“58 (82.9%) female and 12 (17.1%) male”

Table 1Find in source

“Age (years) | 47.7 (10.3) | 46.9 (10.4) | 47.3 (10.3)”

Table 1Find in source

paraphrase[Table 1]

“Ethnicity, n (%) | Asian | 0 (0.0) | 2 (5.7) | 2 (2.9)”

PASSReviewer 2· 90% conf

Biological variables are well reported for a human trial, including sex, age, weight, BMI, and demographics.

Evidence

“Seventy participants (mean (s.d.) age = 47.3 (10.3) years, 58 (82.9%) female and 12 (17.1%) male) were randomized”

AbstractFind in source

paraphrase[Table 1]

“Ethnicity, n (%) | Asian | 0 (0.0) | 2 (5.7) | 2 (2.9) | Black | 10 (28.6) | 6 (17.1) | 16 (22.9) | White | 21 (60.0) | 26 (74.3) | 47 (67.1) | Mixed/other | 4 (11.4) | 1 (2.9) | 5 (7.1)”

The trial was approved by a named ethics committee (London Surrey Borders Research Ethics Committee) with a protocol number. Informed consent is mentioned. Compliance with the Declaration of Helsinki and GCP is stated. The trial is registered.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethical approval and informed consent are clearly documented.

Evidence

“The trial was approved by the London Surrey Borders Research Ethics Committee (no. 22/LO/0045)”

EthicsFind in source

“Written informed consent was obtained”

MethodsFind in source

“conducted in accordance with the Declaration of Helsinki, the principles of good clinical practice and all applicable regulatory requirements”

EthicsFind in source

PASSReviewer 2· 95% conf

Ethical approvals are clearly documented with a named ethics committee, informed consent, and regulatory compliance.

Evidence

“The trial was approved by the London Surrey Borders Research Ethics Committee (no. 22/LO/0045)”

EthicsFind in source

“Written informed consent was obtained”

MethodsFind in source

“conducted in accordance with the Declaration of Helsinki, the principles of good clinical practice and all applicable regulatory requirements”

EthicsFind in source

Semaglutide is identified as 'semaglutide 2.4 mg weekly (Novo Nordisk)' and placebo as 'saline solution'. The dose and regimen are described. Statistical software R version is identified. No antibodies, cell lines, or organisms are used, so those are not applicable.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

The investigational product (semaglutide) and key reagents are identified, and software is specified.

Evidence

“semaglutide 2.4 mg weekly (Novo Nordisk)”

MethodsFind in source

“Merck Active GLP-1 ELISA Kit”

MethodsFind in source

“Analyses were conducted in R (v.2024.12.1+563).”

Statistical analysisFind in source

PASSReviewer 2· 90% conf

The investigational product (semaglutide) and placebo are identified with manufacturer and dose; software is identified.

Evidence

“semaglutide 2.4 mg weekly (Novo Nordisk) ( n = 35) or placebo (saline solution) ( n = 35)”

MethodsFind in source

“Analyses were conducted in R (v.2024.12.1+563).”

Statistical analysisFind in source

Tests are named (linear regression, chi-squared, Fisher's exact, log-binomial regression). Assumptions are checked visually. Exact p-values are reported (e.g., P < 0.001). Effect sizes with 95% CIs are provided. Software is identified. Data presentation includes individual data points (waterfall plot) and error bars defined. Mathematical plausibility checks were not possible for all values, but no obvious errors found.

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical methods are appropriate and well-described, with exact p-values and effect sizes with confidence intervals.

Evidence

“The primary outcome was analyzed using a linear regression model, adjusted for baseline weight, type of surgery, sex and diabetes status, according to the ITT principle.”

Statistical analysisFind in source

“The mean adjusted treatment difference for %WL in placebo versus semaglutide at 68 weeks was −19.1% (95% CI −23.4 to −14.8) ( P < 0.001)”

ResultsFind in source

“The normality assumptions of models were visually checked where appropriate; no transformations or nonparametric methods were used.”

Statistical analysisFind in source

PASSReviewer 2· 90% conf

Statistical methods are well described, with named tests, effect sizes with CIs, and appropriate data presentation for a clinical trial.

Evidence

“The primary outcome was analyzed using a linear regression model, adjusted for baseline weight, type of surgery, sex and diabetes status, according to the ITT principle.”

Statistical analysisFind in source

“The mean adjusted treatment difference in percentage body weight change for semaglutide 2.4 mg versus placebo was −19.18 (95% confidence interval −23.4 to −14.8; P < 0.001).”

AbstractFind in source

“The normality assumptions of models were visually checked where appropriate; no transformations or nonparametric methods were used.”

Statistical analysisFind in source

The data availability statement describes a managed access process with a timeframe. Code is available on GitHub. Repository deposit and accession numbers are not applicable for patient-level data.

Sub-criteria

code sharingADEQUATE

accession numbersN/A

repository depositN/A

data availability statementADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Data availability statement is present with a concrete access route, and code is shared publicly.

Evidence

“Individual participant data collected during the trial, after deidentification, the study protocol, statistical analysis plan and the patient information sheet (consent form) can be shared on request. Study data can be requested after publication through the corresponding author. An initial response to the request will be provided within 2 weeks; if additional approvals are required, the final response time may take up to 6 months.”

Data availabilityFind in source

“Code for the analysis is publicly available and available without restriction via GitHub at https://github.com/SamuelJDicken/BARI-STEP”

Data availabilityFind in source

PASSReviewer 2· 90% conf

Data availability statement is concrete, and code is publicly available on GitHub.

Evidence

Data availabilityFind in source

“Code for the analysis is publicly available and available without restriction via GitHub at https://github.com/SamuelJDicken/BARI-STEP”

Data availabilityFind in source

The trial is registered (NCT05073835). CONSORT guideline is followed. All pre-specified outcomes are reported, including non-significant ones. Limitations are thoroughly discussed. Conclusions are proportional. Funding sources and competing interests are declared.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The manuscript is transparent with complete methods, trial registration, CONSORT adherence, and discussion of limitations.

Evidence

“ClinicalTrials.gov: NCT05073835”

AbstractFind in source

“The study followed the CONSORT reporting guideline.”

EthicsFind in source

“Limitations of our study include only recruiting patients after primary MBS surgery (with a small sample size of GB patients).”

LimitationsFind in source

PASSReviewer 2· 95% conf

Reporting is transparent with trial registration, CONSORT adherence, limitations discussed, and funding/COI statements.

Evidence

“The trial was registered at ClinicalTrials.gov (registration: NCT05073835 (https://clinicaltrials.gov/ct2/show/NCT05073835) )”

EthicsFind in source

“The study followed the CONSORT reporting guideline.”

EthicsFind in source

“Limitations of our study include only recruiting patients after primary MBS surgery (with a small sample size of GB patients).”

Discussion ¶8Find in source

Registered (2 IDs: ClinicalTrials.gov, EudraCT). Reporting guideline cited: CONSORT.

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 41 references by DOI: 40 verified — 1 no DOI (shown, not verified).

1 data/code link checked; 1 live.

Copyediting

5 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 5 minor suggestions below.

5 copyedit issues flagged: mostly consistency, typo.

Kaimen Rigor Action ItemsFinal pass before journal submission

The published work is robust and generally reliable, but readers should weigh the minor internal inconsistency in serious adverse event counts (abstract vs. results) and the slightly overstated claim about rivaling revisional surgery. These do not invalidate the primary findings but warrant clarification or a correction.

1.
HIGHreporting
Reconcile the serious adverse event count: the abstract states 'eight serious AEs' while the results/Table 4 report 12 SAEs (11 SAEs and one SUSAR). Clarify whether this is events vs. patients or a counting error, and correct the abstract or results accordingly.
An internal contradiction in a safety outcome is a validity concern that readers and regulators will flag.
2.
HIGHrigor
Temper the claim that semaglutide 2.4 mg 'may rival weight loss results from revisional metabolic surgery' in the Discussion, since no head-to-head comparison exists and the authors themselves note variability in revisional surgery outcomes.
Overstating a conclusion beyond the evidence is a common reviewer objection and could mislead readers.
3.
MEDIUMcopyedit
Fix the typo 'IQWOL-Lite' to 'IWQOL-Lite' in the Discussion.
Correct terminology is essential for clarity and professionalism.
4.
MEDIUMcopyedit
Standardize the primary outcome value: use −19.2% (or −19.18%) consistently in the Abstract and Results, and ensure the decimal places match.
Minor numerical inconsistency between abstract and results can confuse readers.
5.
MEDIUMcopyedit
Clarify the wording in Results, Categorical weight loss: change 'lost less than 10% weight loss' to 'lost less than 10% of their body weight'.
The current phrasing is grammatically awkward and could be misinterpreted.
6.
MEDIUMcopyedit
In the Abstract, expand 'Eight serious AEs' to 'Eight serious adverse events (SAEs)' for consistency with the rest of the paper.
Consistent use of terminology improves readability and avoids ambiguity.
7.
LOWdata code
Consider providing a more detailed data-sharing mechanism, such as a named repository or data access committee, in the Data Availability statement.
A more concrete access route enhances transparency and reproducibility.
8.
LOWstatistics
Report exact p-values for all secondary outcomes, even exploratory ones, instead of threshold-only values where applicable.
Exact p-values improve transparency and allow readers to assess evidence strength.
9.
LOWreporting
Add a statement on whether any analyses were pre-registered beyond the trial registration, and provide a link to the full statistical analysis plan in the Data Availability statement.
This strengthens transparency and helps readers verify that analyses were pre-specified.
10.
LOWstatistics
Report the results of normality checks in more detail, including any violations and how they were handled, and provide model diagnostics for secondary outcomes.
Detailed assumption checks and diagnostics increase confidence in the statistical methods.
11.
LOWstatistics
Add a sensitivity analysis excluding participants with protocol deviations to assess robustness of the primary findings.
Sensitivity analyses strengthen the credibility of the results.
12.
LOWreporting
Report the number of participants who discontinued due to adverse events separately for each arm, and consider a CONSORT-style flow diagram for secondary outcomes.
Detailed safety reporting and flow diagrams improve completeness and transparency.

Full text (71,735 chars)Analyzed: Aug 15, 2026

Start the discussion on JRNLClub

Community discussion on jrnlclub.com

Read alongside

Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial.

Read full text (PMC)

DOI

10.1038/s41591-026-04416-4

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/0520c931-38e8-486d-b7e7-b11ea8212edb" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/0520c931-38e8-486d-b7e7-b11ea8212edb/badge" alt="Kaimen Rigor review — 3.5★ (Adequate), 0 critical, 2 high issues for “Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

e17cf994ad222cb514355f4fdb4564d117fdab12392d817cef881635ae42198f

Verify via API

Issued Aug 15, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Kaimen Rigor review

Kaimen Rigor reviewed

3.5 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsOverstated claim−0.5★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Biggest issues

01Conclusion reaches beyond the evidence
mediumOverreachreviewer-assessedFull detail
Semaglutide 2.4 mg may rival weight loss results from revisional metabolic surgery.
“Additionally, we provide important clinical evidence that 68 weeks of semaglutide 2.4 mg weekly may rival weight loss results from revisional metabolic surgery when undertaken for weight optimization after a suboptimal outcome to a primary surgical procedure”
Discussion ¶5Find in source

Findings by category

101ArithmeticNumerical inconsistencies 202OverreachOverstated conclusions 03AuthenticityNone found 04DisclosureNone found 05AvailabilityNone found 06Copyedit5 minor suggestions

Numerical inconsistencies

1 finding · worst low

Internal contradictions in the reported numbersAssessed

Recomputed 7 tests: 7 consistent, 0 inconsistent; 2 recomputed directly from the reported test statistics, 5 via agent-written checks.

Overstated conclusions

2 findings · worst medium

Conclusions overstated beyond the evidenceAssessed
Conclusions only partially backed by the presented evidenceAssessed

Efficacy claim is anchored to an adequate endpoint and a meaningful effect.

Data authenticity concerns

None found

Checked — nothing surfaced.

Reporting gaps

None found

Checked — nothing surfaced.

Eight Dimensions8 pass

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise with extensive prior work cited, a logical rationale, and addresses limitations of prior research.

Evidence

Introduction ¶3Find in source

IntroductionFind in source

paraphrase[Discussion, paragraph 2]

“Paraphrase: The authors note that BARI-OPTIMISE selectively recruited patients with blunted GLP-1 response, and BARI-STEP does not require this, addressing a potential limitation.”

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise with extensive prior work cited, a logical rationale, and addresses limitations of prior research.

Evidence

“To our knowledge, there is no randomized clinical trial evaluating the safety and efficacy of semaglutide 2.4 mg for a suboptimal clinical response after MBS.”

Introduction ¶4Find in source

“we hypothesized that once-weekly semaglutide 2.4 mg will lead to greater weight loss and health improvement compared to placebo in patients with a suboptimal clinical response after MBS.”

Introduction ¶4Find in source

Discussion ¶3Find in source

Sub-criteria

controlsN/A

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous with adequate randomization, blinding, power analysis, and pre-specified inclusion/exclusion criteria.

Evidence

“Randomization was carried out by a computer-generated randomization sequence (sealed envelope) stratified according to surgical procedure type (GB versus SG), sex and T2D status.”

MethodsFind in source

“Written informed consent was obtained and all participants and clinical study personnel were blinded.”

MethodsFind in source

PASSReviewer 2· 95% conf

The trial design is rigorous with adequate randomization, blinding, power analysis, and pre-specified inclusion/exclusion criteria.

Evidence

“Randomization was carried out by a computer-generated randomization sequence (sealed envelope) stratified according to surgical procedure type (GB versus SG), sex and T2D status.”

MethodsFind in source

“Written informed consent was obtained and all participants and clinical study personnel were blinded.”

MethodsFind in source

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Biological variables including sex, age, weight, and demographics are well reported.

Evidence

“58 (82.9%) female and 12 (17.1%) male”

Table 1Find in source

“Age (years) | 47.7 (10.3) | 46.9 (10.4) | 47.3 (10.3)”

Table 1Find in source

paraphrase[Table 1]

“Ethnicity, n (%) | Asian | 0 (0.0) | 2 (5.7) | 2 (2.9)”

PASSReviewer 2· 90% conf

Biological variables are well reported for a human trial, including sex, age, weight, BMI, and demographics.

Evidence

“Seventy participants (mean (s.d.) age = 47.3 (10.3) years, 58 (82.9%) female and 12 (17.1%) male) were randomized”

AbstractFind in source

paraphrase[Table 1]

“Ethnicity, n (%) | Asian | 0 (0.0) | 2 (5.7) | 2 (2.9) | Black | 10 (28.6) | 6 (17.1) | 16 (22.9) | White | 21 (60.0) | 26 (74.3) | 47 (67.1) | Mixed/other | 4 (11.4) | 1 (2.9) | 5 (7.1)”

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethical approval and informed consent are clearly documented.

Evidence

“The trial was approved by the London Surrey Borders Research Ethics Committee (no. 22/LO/0045)”

EthicsFind in source

“Written informed consent was obtained”

MethodsFind in source

“conducted in accordance with the Declaration of Helsinki, the principles of good clinical practice and all applicable regulatory requirements”

EthicsFind in source

PASSReviewer 2· 95% conf

Ethical approvals are clearly documented with a named ethics committee, informed consent, and regulatory compliance.

Evidence

“The trial was approved by the London Surrey Borders Research Ethics Committee (no. 22/LO/0045)”

EthicsFind in source

“Written informed consent was obtained”

MethodsFind in source

“conducted in accordance with the Declaration of Helsinki, the principles of good clinical practice and all applicable regulatory requirements”

EthicsFind in source

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

The investigational product (semaglutide) and key reagents are identified, and software is specified.

Evidence

“semaglutide 2.4 mg weekly (Novo Nordisk)”

MethodsFind in source

“Merck Active GLP-1 ELISA Kit”

MethodsFind in source

“Analyses were conducted in R (v.2024.12.1+563).”

Statistical analysisFind in source

PASSReviewer 2· 90% conf

The investigational product (semaglutide) and placebo are identified with manufacturer and dose; software is identified.

Evidence

“semaglutide 2.4 mg weekly (Novo Nordisk) ( n = 35) or placebo (saline solution) ( n = 35)”

MethodsFind in source

“Analyses were conducted in R (v.2024.12.1+563).”

Statistical analysisFind in source

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical methods are appropriate and well-described, with exact p-values and effect sizes with confidence intervals.

Evidence

“The primary outcome was analyzed using a linear regression model, adjusted for baseline weight, type of surgery, sex and diabetes status, according to the ITT principle.”

Statistical analysisFind in source

“The mean adjusted treatment difference for %WL in placebo versus semaglutide at 68 weeks was −19.1% (95% CI −23.4 to −14.8) ( P < 0.001)”

ResultsFind in source

“The normality assumptions of models were visually checked where appropriate; no transformations or nonparametric methods were used.”

Statistical analysisFind in source

PASSReviewer 2· 90% conf

Statistical methods are well described, with named tests, effect sizes with CIs, and appropriate data presentation for a clinical trial.

Evidence

“The primary outcome was analyzed using a linear regression model, adjusted for baseline weight, type of surgery, sex and diabetes status, according to the ITT principle.”

Statistical analysisFind in source

“The mean adjusted treatment difference in percentage body weight change for semaglutide 2.4 mg versus placebo was −19.18 (95% confidence interval −23.4 to −14.8; P < 0.001).”

AbstractFind in source

“The normality assumptions of models were visually checked where appropriate; no transformations or nonparametric methods were used.”

Statistical analysisFind in source

The data availability statement describes a managed access process with a timeframe. Code is available on GitHub. Repository deposit and accession numbers are not applicable for patient-level data.

Sub-criteria

code sharingADEQUATE

accession numbersN/A

repository depositN/A

data availability statementADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Data availability statement is present with a concrete access route, and code is shared publicly.

Evidence

Data availabilityFind in source

“Code for the analysis is publicly available and available without restriction via GitHub at https://github.com/SamuelJDicken/BARI-STEP”

Data availabilityFind in source

PASSReviewer 2· 90% conf

Data availability statement is concrete, and code is publicly available on GitHub.

Evidence

Data availabilityFind in source

“Code for the analysis is publicly available and available without restriction via GitHub at https://github.com/SamuelJDicken/BARI-STEP”

Data availabilityFind in source

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The manuscript is transparent with complete methods, trial registration, CONSORT adherence, and discussion of limitations.

Evidence

“ClinicalTrials.gov: NCT05073835”

AbstractFind in source

“The study followed the CONSORT reporting guideline.”

EthicsFind in source

“Limitations of our study include only recruiting patients after primary MBS surgery (with a small sample size of GB patients).”

LimitationsFind in source

PASSReviewer 2· 95% conf

Reporting is transparent with trial registration, CONSORT adherence, limitations discussed, and funding/COI statements.

Evidence

“The trial was registered at ClinicalTrials.gov (registration: NCT05073835 (https://clinicaltrials.gov/ct2/show/NCT05073835) )”

EthicsFind in source

“The study followed the CONSORT reporting guideline.”

EthicsFind in source

“Limitations of our study include only recruiting patients after primary MBS surgery (with a small sample size of GB patients).”

Discussion ¶8Find in source

Registered (2 IDs: ClinicalTrials.gov, EudraCT). Reporting guideline cited: CONSORT.

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 41 references by DOI: 40 verified — 1 no DOI (shown, not verified).

1 data/code link checked; 1 live.

Copyediting

5 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 5 minor suggestions below.

5 copyedit issues flagged: mostly consistency, typo.

Kaimen Rigor Action ItemsFinal pass before journal submission

1.
HIGHreporting
Reconcile the serious adverse event count: the abstract states 'eight serious AEs' while the results/Table 4 report 12 SAEs (11 SAEs and one SUSAR). Clarify whether this is events vs. patients or a counting error, and correct the abstract or results accordingly.
An internal contradiction in a safety outcome is a validity concern that readers and regulators will flag.
2.
HIGHrigor
Temper the claim that semaglutide 2.4 mg 'may rival weight loss results from revisional metabolic surgery' in the Discussion, since no head-to-head comparison exists and the authors themselves note variability in revisional surgery outcomes.
Overstating a conclusion beyond the evidence is a common reviewer objection and could mislead readers.
3.
MEDIUMcopyedit
Fix the typo 'IQWOL-Lite' to 'IWQOL-Lite' in the Discussion.
Correct terminology is essential for clarity and professionalism.
4.
MEDIUMcopyedit
Standardize the primary outcome value: use −19.2% (or −19.18%) consistently in the Abstract and Results, and ensure the decimal places match.
Minor numerical inconsistency between abstract and results can confuse readers.
5.
MEDIUMcopyedit
Clarify the wording in Results, Categorical weight loss: change 'lost less than 10% weight loss' to 'lost less than 10% of their body weight'.
The current phrasing is grammatically awkward and could be misinterpreted.
6.
MEDIUMcopyedit
In the Abstract, expand 'Eight serious AEs' to 'Eight serious adverse events (SAEs)' for consistency with the rest of the paper.
Consistent use of terminology improves readability and avoids ambiguity.
7.
LOWdata code
Consider providing a more detailed data-sharing mechanism, such as a named repository or data access committee, in the Data Availability statement.
A more concrete access route enhances transparency and reproducibility.
8.
LOWstatistics
Report exact p-values for all secondary outcomes, even exploratory ones, instead of threshold-only values where applicable.
Exact p-values improve transparency and allow readers to assess evidence strength.
9.
LOWreporting
Add a statement on whether any analyses were pre-registered beyond the trial registration, and provide a link to the full statistical analysis plan in the Data Availability statement.
This strengthens transparency and helps readers verify that analyses were pre-specified.
10.
LOWstatistics
Report the results of normality checks in more detail, including any violations and how they were handled, and provide model diagnostics for secondary outcomes.
Detailed assumption checks and diagnostics increase confidence in the statistical methods.
11.
LOWstatistics
Add a sensitivity analysis excluding participants with protocol deviations to assess robustness of the primary findings.
Sensitivity analyses strengthen the credibility of the results.
12.
LOWreporting
Report the number of participants who discontinued due to adverse events separately for each arm, and consider a CONSORT-style flow diagram for secondary outcomes.
Detailed safety reporting and flow diagrams improve completeness and transparency.

Full text (71,735 chars)Analyzed: Aug 15, 2026